Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of selective small molecule MDM2 degraders based on nutlin
Bo Wang, Suzhen Wu, Jin Liu, et al.
European Journal of Medicinal Chemistry (2019) Vol. 176, pp. 476-491
Closed Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 498
Targeting p53 pathways: mechanisms, structures and advances in therapy
Haolan Wang, Ming Guo, Hudie Wei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 322
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5
Open Access | Times Cited: 247
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 173
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Aleša Bricelj, Christian Steinebach, Robert D. Kuchta, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 158
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 156
Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
Yaxian Zhou, Peng Teng, Nathan T. Montgomery, et al.
ACS Central Science (2021) Vol. 7, Iss. 3, pp. 499-506
Open Access | Times Cited: 143
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 137
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
Haohao Zhu, Hui Gao, Yingying Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 129
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 88
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1210-1229
Open Access | Times Cited: 58
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 28
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 93
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Yuan Fang, Guochao Liao, Bin Yu
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 7, pp. 1253-1278
Open Access | Times Cited: 78
Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
Yu-Ling Tseng, Po-Chao Lu, Chi-Chang Lee, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 30
A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders
Ka Yang, Yu Zhao, Xueqing Nie, et al.
Cell chemical biology (2020) Vol. 27, Iss. 7, pp. 866-876.e8
Open Access | Times Cited: 66
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)
Fangyuan Cao, Sander de Weerd, Deng Chen, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112800-112800
Open Access | Times Cited: 63
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
Shipeng He, Junhui Ma, Yuxin Fang, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 6, pp. 1617-1628
Open Access | Times Cited: 61
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
Bo Wang, Jin Liu, Ira Tandon, et al.
European Journal of Medicinal Chemistry (2021) Vol. 219, pp. 113425-113425
Open Access | Times Cited: 46
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
Donghuan Sun, Jing Zhang, Guoqiang Dong, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 21, pp. 14276-14288
Closed Access | Times Cited: 36
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Jianyu Yan, Tengfei Li, Zhenyuan Miao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8798-8827
Closed Access | Times Cited: 28
Small-molecule correctors and stabilizers to target p53
Maryam M.J. Fallatah, Fiona V. Law, Warren Chow, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 274-289
Open Access | Times Cited: 20
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Hong‐Yi Zhao, Minhang Xin, San‐Qi Zhang
Drug Development Research (2023) Vol. 84, Iss. 2, pp. 337-394
Closed Access | Times Cited: 16
E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities
Qiang Zou, Meng Liu, Kewei Liu, et al.
Cellular Oncology (2023) Vol. 46, Iss. 3, pp. 545-570
Open Access | Times Cited: 16
An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy
Huiwen Li, Xinhui Cai, Xiaoyu Yang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116506-116506
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top